Interaction of levofloxacin with lung surfactant at the air-water interface

Autor(es)

Ortiz-Collazos, Stephanie ^[1] ; Estrada-Lopez, Evelina D. ^[1] ; Pedreira, Alline A. ^[1] ; Picciani, Paulo H. S. ^[2] ; Oliveira, Jr., Osvaldo N. ^[3] ; Pimentel, Andre S. ^[1]

Afiliação do(s) autor(es)

^[1] Pontificia Univ Catolica Rio de Janeiro, Dept Quim, BR-22453900 Rio De Janeiro, RJ - Brazil

^[2] Univ Fed Rio de Janeiro, Inst Macromol Prof Eloisa Mano, BR-21941598 Rio De Janeiro, RJ - Brazil

^[3] Univ Sao Paulo, Inst Fis Sao Carlos, BR-13566590 Sao Carlos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: COLLOIDS AND SURFACES B-BIOINTERFACES; v. 158, p. 689-696, OCT 1 2017.
• Citações Web of Science: 11

Resumo

The molecular-level interaction of levofloxacin with lung surfactant was investigated using Langmuir monolayers and atomistic molecular dynamics (MD) simulations. In the simulation, the DPPC/POPC mixed monolayer was used as a lung surfactant model and the molecules of levofloxacin were placed at the air-lipid interface to mimic the adsorption process on the lung surfactant model. The simulation results indicate that amphoteric levofloxacin expands the lung surfactant, also stabilizing the film for levofloxacin fractions until 10% w/w at least. The Langmuir monolayers made with the lung surfactant Curosurf had expanded isotherms upon incorporation of levofloxacin, without changes in monolayer elasticity. In fact, levofloxacin induced film stability with increased collapse pressures in the Curosurf isotherms and delayed the phase transition, according to Brewster angle microscopy (BAM) imaging. Using polarization-modulated infrared reflection-absorption spectroscopy (PM-IRRAS), we found that levofloxacin is preferentially located in the head group region, inducing an increased organization of the Curosurf film. This location of levofloxacin was confirmed with MD simulations. The stability inferred demonstrates that the lung surfactant can be used as a drug delivery system for the administration via inhalation or intratracheal instillation of levofloxacin to treat lung diseases such as pneumonia and respiratory distress syndrome. (C) 2017 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 13/14262-7 - Filmes nanoestruturados de materiais de interesse biológico
• Beneficiário: Osvaldo Novais de Oliveira Junior
• Modalidade de apoio: Auxílio à Pesquisa - Temático